Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB01016_nanopub.RAy90aiIrZcpzUBJ3QXAl4x4NVcR-Bdjubm8jY3a1selI#assertion>. }
Showing items 1 to 28 of
28
with 100 items per page.
- drugbank:DB01016 type drugbank_vocabulary:Drug assertion.
- drugbank:DB01016 label "Glyburide [drugbank:DB01016]" assertion.
- drugbank:DB01016 seeAlso DB01016 assertion.
- drugbank:DB01016 seeAlso glybur.htm assertion.
- drugbank:DB01016 identifier "drugbank:DB01016" assertion.
- drugbank:DB01016 description "Glyburide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Glyburide has been shown to decrease fasting plasma glucose, postprandial blood glucose and glycosolated hemoglobin (HbA1c) levels (reflective of the last 8-10 weeks of glucose control). Glyburide appears to be completely metabolized, likely in the liver. Although its metabolites exert a small hypoglycemic effect, their contribution to glyburide's hypoglycemic effect is thought to be clinically unimportant. Glyburide metabolites are excreted in urine and feces in approximately equal proportions. The half-life of glyburide appears to be unaffected in those with a creatinine clearance of greater than 29 ml/min/1.73m<sup>2</sup>." assertion.
- drugbank:DB01016 title "Glyburide" assertion.
- drugbank:DB01016 bio2rdf_vocabulary:identifier "DB01016" assertion.
- drugbank:DB01016 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB01016 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB01016" assertion.
- drugbank:DB01016 bio2rdf_vocabulary:x-identifiers.org DB01016 assertion.
- drugbank:DB01016 drugbank_vocabulary:drugbank-id "APRD00233" assertion.
- drugbank:DB01016 drugbank_vocabulary:drugbank-id "DB01016" assertion.
- drugbank:DB01016 drugbank_vocabulary:x-cas cas:10238-21-8 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-chemspider chemspider:3368 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-pubchemcompound pubchem.compound:3488 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-pubchemsubstance pubchem.substance:46509154 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-ahfs ahfs:68:20.20 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-atc atc:A10BB01 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-chebi chebi:5441 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-dpd dpd:2248008 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-kegg kegg:C07022 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-kegg kegg:D00336 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-pharmgkb pharmgkb:PA449782 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-wikipedia wikipedia:Glibenclamide assertion.
- drugbank:DB01016 drugbank_vocabulary:x-ndc ndc:0378-1113-01 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-gtp gtp:2414 assertion.
- drugbank:DB01016 drugbank_vocabulary:x-iuphar iuphar:2414 assertion.